Curated News
By: NewsRamp Editorial Staff
May 29, 2024

Clene Announces Key Updates on NIH-Funded Expanded Access Program for CNM-Au8 Compassionate Use in ALS

Reddit Discuss on RedditDiscuss on Substack Discuss on Substack
Source News Release

TLDR

  • Clene's CNM-Au8 treatment has shown lowered risk of death and delayed clinical worsening in ALS, offering a potential advantage for patients.
  • The treatment utilizes a first-in-class therapy that targets mitochondrial function and the NAD pathway, improving CNS cells' survival and function.
  • The EAP for CNM-Au8 in ALS can provide access to potentially life-saving treatment for a broader ALS population, offering hope to those living with the disease.
  • Clene's CNM-Au8 treatment has been associated with lowered risk of death and delayed clinical worsening, showing promise for ALS patients.

Impact - Why it Matters

This news matters because it highlights the progress and potential impact of Clene's investigational drug CNM-Au8 in providing a treatment option for the ALS community. The positive results from the Phase 2 clinical studies and the NIH-funded EAP demonstrate the company's commitment to improving mitochondrial health and protecting neuronal function in neurodegenerative diseases.

Summary

Clene (NASDAQ: CLNN) and its subsidiary Clene Nanomedicine Inc. have announced key updates on the NIH funded Accelerating Access to Critical Therapies Expanded Access Program for CNM-Au8 compassionate use in ALS. The EAP aims to provide access to the investigational drug CNM-Au8 for the ALS community, following positive results from independent Phase 2 clinical studies. The company is grateful for the NIH's recognition and the FDA's approval of this initiative.

Clene is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases. Its investigational drug CNM-Au8 has shown promise in improving the survival and function of central nervous system cells, with a focus on targeting mitochondrial function and reducing oxidative stress.

Source Statement

This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Clene Announces Key Updates on NIH-Funded Expanded Access Program for CNM-Au8 Compassionate Use in ALS

blockchain registration record for the source press release.